© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 01, 2022
Real-world research show the tolerability and effectiveness of trifluridine and tipiracil combined with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer.
November 23, 2022
Preclinical data shows the potential of oxMIF as a new immuno-oncology target which may be helpful in treating patients with metastatic colorectal cancers
November 21, 2022
Olumide B. Gbolahan, MBBS, MSc, discusses the key biomarkers oncologists should test for to determine the optimal treatment for patients with colorectal cancer (CRC).
November 01, 2022
A phase 1/2 study of ZN-c3, encorafenib, and cetuximab in patients with BRAF V600E-mutated colorectal cancer will begin, led by Zentalis Pharmaceuticals and Pfizer.
October 03, 2022
Investigators recommend that genomic testing be adopted to be a reflexive and natural step in evaluating patients with non–small cell lung cancer and colorectal cancer/
September 12, 2022
The use of adagrasib in combination with cetuximab or alone elicted encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.
Tucatinib alone and with trastuzumab supported further investigation of each regimen in metastatic HER2-positive colorectal cancer.
September 11, 2022
At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.
August 22, 2022
The combination of botensilimab and balstilimab showed robust response rate, durability, and tolerability in a patients with microsatellite stable colorectal cancer.
Recent data reported from the MOUNTAINEER will support a new drug application for tucatinib in patients with metastatic colorectal cancer.